$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

네트워크 약리학적 분석에 의한 소세포폐암에 대한 청대의 항암기전 연구
Identifying the Anti-Cancer Effect of Indigo Naturalis in Small Cell Lung Cancer Based on Network Pharmacological Analysis 원문보기

동의생리병리학회지 = Journal of physiology & pathology in Korean Medicine, v.36 no.6, 2022년, pp.229 - 234  

김영훈 (부산대학교 한의학전문대학원) ,  정우진 (부산대학교 한의학전문대학원) ,  정광희 (부산대학교 한의학전문대학원) ,  김윤숙 (부산대학교 장수웰빙연구소) ,  안원근 (부산대학교 한의학전문대학원)

Abstract AI-Helper 아이콘AI-Helper

Lung cancer is the leading cause of cancer-related deaths worldwide. Indigo Naturalis (IN) is a dark blue powder obtained by processing leaves or stems of indigo plants, its anticancer effects have been reported in several studies. However, the pharmacological mechanism of IN in small cell lung canc...

주제어

표/그림 (7)

참고문헌 (43)

  1. International Agency for Research on Cancer. Global?Cancer Observatory: Cancer Today. Available from:?https://gco.iarc.fr/today/fact-sheets-cancers [Accessed?28th September 2022]. 

  2. Byers LA, Rudin CM. Small cell lung cancer: where do?we go from here? Cancer. 2015;121(5):664-72. 

  3. Herzog BH, Devarakonda S, Govindan R. Overcoming?Chemotherapy Resistance in SCLC. J Thorac Oncol.?2021;16(12):2002-15. 

  4. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell?lung cancer. Nat Rev Dis Primers. 2021;7(1):1-20. 

  5. Minami T, Kijima T, Kohmo S, Arase H, Otani Y,?Nagatomo I, et al. Overcoming chemoresistance of?small-cell lung cancer through stepwise HER2-targeted?antibody-dependent cell-mediated cytotoxicity and?VEGF-targeted antiangiogenesis. Sci Rep.?2013;3:2669:1-11. 

  6. Quaresma M, Coleman MP, Rachet B. 40-year trends in?an index of survival for all cancers combined and?survival adjusted for age and sex for each cancer in?England and Wales, 1971-2011: a population-based?study. Lancet. 2015;385(9974):1206-18. 

  7. Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis?F, Rosell R. Cellular and molecular biology of small cell?lung cancer: an overview. Transl Lung Cancer Res.?2016;5(1):2-15. 

  8. Cancer.Net Editorial Board. Lung cancer - small cell - statistics. Available from:?https://www.cancer.net/cancer-types/lung-cancer-small-cell/statistics [Accessed 28th September 2022]. 

  9. Pezzani R, Salehi B, Vitalini S, Iriti M, Zuniga FA,?Sharifi-Rad J, et al. Synergistic Effects of Plant?Derivatives and Conventional Chemotherapeutic Agents:?An Update on the Cancer Perspective. Medicina?(Kaunas). 2019;55(4):1-16. 

  10. Castaneda AM, Melendez CM, Uribe D, Pedroza-Diaz J.?Synergistic effects of natural compounds and?conventional chemotherapeutic agents: recent insights?for the development of cancer treatment strategies.?Heliyon. 2022;8(6):e09519. 

  11. Liu Z, Ma L, Zhou GB. The main anticancer bullets of?the Chinese medicinal herb, thunder god vine.?Molecules. 2011;16(6):5283-97. 

  12. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, et al.?Anti-cancer natural products isolated from chinese?medicinal herbs. Chin Med. 2011;6(1):27:1-15. 

  13. Stasiak N, Kukula-Koch W, Glowniak K. Modern industrial?and pharmacological applications of indigo dye and its?derivatives-a review. Acta Pol Pharm. 2014;71(2):215-21. 

  14. State Pharmacopoeia Commission of the PRC.?Pharmacopoeia of the People's Republic of China.?China: People's Medical Publishing House; 2005. 

  15. Tang W., Eisenbrand G. Chinese Drugs of Plant Origin:?Chemistry, Pharmacology, and Use in Traditional and?Modern Medicine. Berlin: Springer-Verlag; 1992. 

  16. Han J. Traditional Chinese medicine and the search for?new antineoplastic drugs. J Ethnopharmacol.?1988;24(1):1-17. 

  17. Yang MH, Wan WQ, Luo JS, Zheng MC, Huang K, Yang?LH, et al. Multicenter randomized trial of arsenic?trioxide and Realgar-Indigo naturalis formula in?pediatric patients with acute promyelocytic leukemia:?Interim results of the SCCLG-APL clinical study. Am J?Hematol. 2018;93(12):1467-73. 

  18. Liau BC, Jong TT, Lee MR, Chen SS. LC-APCI-MS?method for detection and analysis of tryptanthrin,?indigo, and indirubin in daqingye and banlangen. J?Pharm Biomed Anal. 2007;43(1):346-51. 

  19. Cao Z, Yang F, Wang J, Gu Z, Lin S, Wang P, et al. Indirubin Derivatives as Dual Inhibitors Targeting?Cyclin-Dependent Kinase and Histone Deacetylase for?Treating Cancer. J Med Chem. 2021;64(20):15280-96. 

  20. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ,?Muehlbeyer S, et al. Indirubin derivatives inhibit Stat3?signaling and induce apoptosis in human cancer cells.?Proc Natl Acad Sci U S A. 2005;102(17):5998-6003. 

  21. Wang H, Wang Z, Wei C, Wang J, Xu Y, Bai G, et al.?Anticancer potential of indirubins in medicinal?chemistry: Biological activity, structural modification,?and structure-activity relationship. Eur J Med Chem.?2021;223:113652:1-30. 

  22. Hsieh WL, Lin YK, Tsai CN, Wang TM, Chen TY, Pang?JH. Indirubin, an acting component of indigo naturalis,?inhibits EGFR activation and EGF-induced CDC25B gene?expression in epidermal keratinocytes. J Dermatol Sci.?2012;67(2):140-6. 

  23. Gao W, Guo Y, Wang C, Lin Y, Yu L, Sheng T, et al.?Indirubin ameliorates dextran sulfate sodium-induced?ulcerative colitis in mice through the inhibition of?inflammation and the induction of Foxp3-expressing?regulatory T cells. Acta Histochem. 2016;118(6):606-14. 

  24. Lin YK, Chang SH, Yang CY, See LC, Lee BH, Shih IH.?Efficacy and safety of indigo naturalis ointment in?Treating Atopic Dermatitis: A randomized clinical trial. J?Ethnopharmacol. 2020;250:112477:1-8. 

  25. Kaur R, Manjal SK, Rawal RK, Kumar K. Recent?synthetic and medicinal perspectives of tryptanthrin.?Bioorg Med Chem. 2017;25(17):4533-52. 

  26. Chiang YR, Li A, Leu YL, Fang JY, Lin YK. An in vitro?study of the antimicrobial effects of indigo naturalis?prepared from Strobilanthes formosanus Moore.?Molecules. 2013;18(11):14381-96. 

  27. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al.?TCMSP: a database of systems pharmacology for drug?discovery from herbal medicines. J Cheminform.?2014;6:13:1-6. 

  28. Daina A, Michielin O, Zoete V. SwissADME: a free web?tool to evaluate pharmacokinetics, drug-likeness and?medicinal chemistry friendliness of small molecules. Sci?Rep. 2017;7:42717:1-13. 

  29. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH,?Tanaseichuk O, et al. Metascape provides a?biologist-oriented resource for the analysis of?systems-level datasets. Nat Commun. 2019;10(1):1523:1-10. 

  30. Liu SG, Luo GP, Qu YB, Chen YF. Indirubin inhibits?Wnt/beta-catenin signal pathway via promoter?demethylation of WIF-1. BMC Complement Med Ther.?2020;20(1):250:1-10. 

  31. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A,?Tunnah P, et al. Indirubin, the active constituent of a?Chinese antileukaemia medicine, inhibits?cyclin-dependent kinases. Nat Cell Biol. 1999;1(1):60-7. 

  32. Premanathan M, Radhakrishnan S, Kulangiappar K,?Singaravelu G, Thirumalaiarasu V, Sivakumar T, et al.?Antioxidant & anticancer activities of isatin?(1H-indole-2,3-dione), isolated from the flowers of?Couroupita guianensis Aubl. Indian J Med Res.?2012;136(5):822-6. 

  33. Chen DL, Zhou D, Chu W, Herrbrich P, Engle JT,?Griffin E, et al. Radiolabeled isatin binding to caspase-3?activation induced by anti-Fas antibody. Nucl Med Biol.?2012;39(1):137-44. 

  34. Ferraz de Paiva RE, Vieira EG, Rodrigues da Silva D,?Wegermann CA, Costa Ferreira AM. Anticancer?Compounds Based on Isatin-Derivatives: Strategies to?Ameliorate Selectivity and Efficiency. Front Mol Biosci.?2020;7:627272:1-24. 

  35. Jahng Y. Progress in the studies on tryptanthrin, an?alkaloid of history. Arch Pharm Res. 2013;36(5):517-35. 

  36. Yuan M, Zhao Y, Arkenau HT, Lao T, Chu L, Xu Q.?Signal pathways and precision therapy of small-cell?lung cancer. Signal Transduct Target Ther.?2022;7(1):187:1-18. 

  37. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM.?Cloning of the chromosome breakpoint of neoplastic B?cells with the t(14;18) chromosome translocation.?Science. 1984;226(4678):1097-9. 

  38. Wang C, Zhang J, Yin J, Gan Y, Xu S, Gu Y, et al.?Alternative approaches to target Myc for cancer?treatment. Signal Transduct Target Ther.?2021;6(1):117:1-14. 

  39. Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS.?Why are there hotspot mutations in the TP53 gene in?human cancers? Cell Death Differ. 2018;25(1):154-60. 

  40. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et?al. Comprehensive genomic profiles of small cell lung?cancer. Nature. 2015;524(7563):47-53. 

  41. el-Deiry WS, Tokino T, Velculescu VE, Levy DB,?Parsons R, Trent JM, et al. WAF1, a potential mediator?of p53 tumor suppression. Cell. 1993;75(4):817-25. 

  42. Karimian A, Ahmadi Y, Yousefi B. Multiple functions of?p21 in cell cycle, apoptosis and transcriptional?regulation after DNA damage. DNA Repair (Amst).?2016;42:63-71. 

  43. Peng H, Yuan X, Shi R, Wei X, Ren S, Yan C, et al.?PHII-7 inhibits cell growth and induces apoptosis in?leukemia cell line K562 as well as its MDR- counterpart?K562/A02 through producing reactive oxygen species.?Eur J Pharmacol. 2013;718(1-3):459-68. 

저자의 다른 논문 :

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로